Pfenex Expects To Be Alone With Teriparatide
Not Expecting Teva Entry Until Later Next Year
Pfenex believes it and commercial partner Alvogen could enjoy an extended period as the only direct competitor to Eli Lilly’s Forteo teriparatide reference brand in the US.
